Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S171000, C514S177000, C514S179000, C514S180000
Reexamination Certificate
active
07915265
ABSTRACT:
The invention features pharmaceutical compositions that include dipyridamole and a corticosteroid.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3934036 (1976-01-01), Irikura
patent: 3944577 (1976-03-01), Laurent et al.
patent: 4034087 (1977-07-01), Voorhees
patent: 4107306 (1978-08-01), Voorhees
patent: 4367217 (1983-01-01), Gruber et al.
patent: 4499093 (1985-02-01), Galabov et al.
patent: 4554271 (1985-11-01), Braughler et al.
patent: 4685911 (1987-08-01), Konno et al.
patent: 4879119 (1989-11-01), Konno et al.
patent: 5051262 (1991-09-01), Panoz et al.
patent: 5242921 (1993-09-01), Milstone et al.
patent: 5270047 (1993-12-01), Kauffman et al.
patent: 5314688 (1994-05-01), Kauffman et al.
patent: 5326764 (1994-07-01), Milstone et al.
patent: 5428040 (1995-06-01), Magolda et al.
patent: 5468729 (1995-11-01), Chretien et al.
patent: 5639759 (1997-06-01), Magolda et al.
patent: 5668116 (1997-09-01), Cullis-Hill et al.
patent: 5728712 (1998-03-01), Montana et al.
patent: 5756553 (1998-05-01), Iguchi et al.
patent: 5762918 (1998-06-01), Thorpe
patent: 5792476 (1998-08-01), Hallgren
patent: 5874437 (1999-02-01), Garvey et al.
patent: 5874441 (1999-02-01), Magolda et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 6010716 (2000-01-01), Saunal et al.
patent: 6015577 (2000-01-01), Eisert et al.
patent: 6054487 (2000-04-01), Sekut et al.
patent: 6071514 (2000-06-01), Grinnell et al.
patent: 6110910 (2000-08-01), Magolda et al.
patent: 6133272 (2000-10-01), Garvey et al.
patent: 6172060 (2001-01-01), Garvey et al.
patent: 6172068 (2001-01-01), Garvey et al.
patent: 6177428 (2001-01-01), Garvey et al.
patent: 6197778 (2001-03-01), Garvey et al.
patent: 6197782 (2001-03-01), Garvey et al.
patent: 6211179 (2001-04-01), Garvey et al.
patent: 6221881 (2001-04-01), Garvey et al.
patent: 6232321 (2001-05-01), Garvey et al.
patent: 6265427 (2001-07-01), Camden
patent: 6316457 (2001-11-01), Garvey et al.
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6337325 (2002-01-01), Schonharting et al.
patent: 6372254 (2002-04-01), Ting et al.
patent: 6383471 (2002-05-01), Chen et al.
patent: 6403571 (2002-06-01), Gould et al.
patent: 6462044 (2002-10-01), Garvey et al.
patent: 6515010 (2003-02-01), Franchini et al.
patent: 6602521 (2003-08-01), Ting et al.
patent: 6677326 (2004-01-01), Bardsley et al.
patent: 6730321 (2004-05-01), Ting et al.
patent: 7253155 (2007-08-01), Keith et al.
patent: 2001/0007083 (2001-07-01), Roorda
patent: 2001/0016604 (2001-08-01), Yu et al.
patent: 2002/0019405 (2002-02-01), Garvey et al.
patent: 2003/0003151 (2003-01-01), Chopra
patent: 2003/0023087 (2003-01-01), Garvey et al.
patent: 2003/0069169 (2003-04-01), Macor et al.
patent: 2003/0077229 (2003-04-01), Dugger, III
patent: 2003/0203028 (2003-10-01), Ting et al.
patent: 2004/0087486 (2004-05-01), Hanson
patent: 2004/0087591 (2004-05-01), Garvey et al.
patent: 2004/0180812 (2004-09-01), Dicker et al.
patent: 2005/0019393 (2005-01-01), Augsburger et al.
patent: 2005/0025713 (2005-02-01), Dugger, III
patent: 2005/0037074 (2005-02-01), Ross et al.
patent: 2005/0058688 (2005-03-01), Boerger et al.
patent: 2005/0119160 (2005-06-01), Keith et al.
patent: 2006/0234991 (2006-10-01), Keith et al.
patent: 2007/0010502 (2007-01-01), Keith et al.
patent: 2007/0196491 (2007-08-01), Venkatesh
patent: 2007/0213296 (2007-09-01), Zhang
patent: 2007/0213308 (2007-09-01), Lessem et al.
patent: 1246335 (2000-03-01), None
patent: 0 303 713 (1988-08-01), None
patent: 0 543 653 (1992-11-01), None
patent: 1 093 814 (2001-04-01), None
patent: 2 292 079 (1996-02-01), None
patent: WO 89/10122 (1989-11-01), None
patent: WO 92/16226 (1992-01-01), None
patent: WO 98/19672 (1998-05-01), None
patent: WO 98/55142 (1998-12-01), None
patent: WO 99/16417 (1999-04-01), None
patent: WO 99/62537 (1999-12-01), None
patent: WO 00/12076 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/59475 (2000-10-01), None
patent: WO 01/02497 (2001-01-01), None
patent: WO 01/47572 (2001-07-01), None
patent: WO 01/54679 (2001-08-01), None
patent: WO 01/68056 (2001-09-01), None
patent: WO 02/22127 (2002-03-01), None
patent: WO 02/085304 (2002-10-01), None
patent: WO 02/094227 (2002-11-01), None
patent: WO 03/043603 (2003-05-01), None
patent: WO 2004/019909 (2004-03-01), None
patent: WO 2004/069254 (2004-08-01), None
patent: WO 2005/020933 (2005-03-01), None
patent: WO 2005/037203 (2005-08-01), None
patent: WO 2007/089617 (2007-08-01), None
patent: WO 2007/103373 (2007-09-01), None
Takeda et al. “Long term corticosteroid and dipyridamole treatment of membranoproliferative glomerulonephritis type I in children,” Japenese Journal of nephrology, 1995, vol. 37, No. 6, pp. 330-335.
Afeltra, “Treatment of Rheumatoid Arthritis: New Therapeutic Approaches with Biological Agents,”Curr. Drug Targets Immune Endocr. Metabol. Disord. 1:45-65 (2001).
Ardizzone et al., “Inflammatory Bowel Disease: New Insights Into Pathogenesis and Treatment,”J. Intern. Med. 252:475-496 (2002).
Badger et al., “Disease-Modifying Activity of SB 242235, A Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, In Rat Adjuvant-Induced Arthritis,”Arthritis. Rheum. 43:175-183 (2000).
Barlow et al., “Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)”Bioorg Med Chem Lett. 10:585-589 (2000).
Barnes, “Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms,”Clin. Sci. 94:557-572 (1998).
Baxter et al., “Mechanism of Glucocorticoid Action: General Features with Reference to Steroid-Mediated Immunosuppression,”Transplant Proc. 7:55-65 (1975).
Beck et al., “Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?”Acta. Neurol. Scand. 78:318-323 (1998).
Berger et al., “Comparative Carcinogenic Activity of Prednimustine, Chlorambucil, Prednisolone and Chlorambucil Plus Prednisolone in Sprague-Dawley Rats,”Arch. Geschwulstforsch. 55:429-442 (1985).
Berger et al., “Long-Term Toxicology Effects of Prednimustine in Comparison with Chlorambucil, Prednisolone, and Chlorambucil Plus Prednisolone in Sprague-Dawley Rats,”Semin. Oncol. 13:8-13 (1986).
Berkow, “Bone, Joint, and Muscle Disorders,” Disorders of Joints and Connective Tissue,The Merck Manual, Home ed., pp. 248-255 (1997).
Berkow, “Chapter 59: Chronic Inflammatory Diseases of the Bowel,” Gastrointestinal Disorders,The Merck Manual, 15thed., pp. 796-807 (1987).
Braun et al., “Anti-tumour Necrosis Factor α Therapy for Ankylosing Spondylitis: International Experience,”Ann. Rheum. Dis. 61:iii51-iii60 (2002).
Braun et al., “Therapy of Ankylosing Spondylitis and Other Spondyloarthritides: Established Medical Treatment, Anti-TNF-α Therapy and Other Novel Approaches,”Arthritis. Res. 4:307-321 (2002).
Brunette et al., “Long-term Immunosuppressive Treatment of a Child with Takayasu's Arteritis and High IgE Immunoglobulins,”Pediatr. Nephrol. 10:67-69 (1996).
Bruserud, “Dipyridamol Inhibits Activation of Human T Lymphocytes In Vitro,”Clin. Immunol. Immunopathol. 42:102-109 (1987).
Cass et al., “A Comparison of the Abilities of Nitrobenzylthioinosine, Dilazep, and Dipyridamole to Protect Human Hematopoietic Cells from 7-Deazaadenosine (Tubercidin)”Cancer Res. 52:5879-5886 (1992).
Cazenave et al., “Inhibition of Platelet Adherence to a Collagen-Coated Surface by Nonsteroidal Anti-Inflammatory Drugs, Pyrimido-Pyrimidine and Tricyclic Compounds, and Lidocaine”J. Lab. Clin. Med. 83:797-806 (1974).
Conway et al., “Inhibition of Cartilage and Bone Destruction in Adjuvant Arthritis in the Rat by a Matrix Metalloproteinase Inhibitor,”J. Exp. Med. 182:449-457 (1995).
Crew et al., “Transgenic Mice Expressing a
Borisy Alexis
Foley Michael A.
Hurst Nicole W.
Jost-Price Edward Roydon
Keith Curtis
Clark & Elbing LLP
Wang Shengjun
Zalicus Inc.
LandOfFree
Combinations for the treatment of immunoinflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations for the treatment of immunoinflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations for the treatment of immunoinflammatory disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2733766